Dual BCL-2/BCL-XL inhibitors are anticipated to deliver therapeutic benefit in many hematological and solid cancers, but their clinical development has also been limited by tolerability and safety issues including thrombocytopenia. The gene discussed is BCL2L1; the disease is Thrombocytopenia.